Search research articles
Contact Us
Filters
Showing results (71-80 of 94) with videos related to
Page
of 10
Sort By:
The Journal of Biological Chemistry
|
January 6, 2007
JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells
Thomas D Hock, Karen Liby, Marcienne M Wright, et al.
Immunology
|
October 3, 2012
Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability
Barry D Hock, Karen G Taylor, Nicholas B Cross, et al.
Leukemia & Lymphoma
|
September 17, 2004
Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies
B D Hock, G C Starling, W N Patton, et al.
Internal Medicine Journal
|
November 24, 2023
Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing
Paula E Keating, Barry D Hock, Stewart M Smith, et al.
Tissue Antigens
|
February 3, 2006
Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients
B D Hock, J L O'Donnell, K Taylor, et al.
Therapeutic Drug Monitoring
|
July 30, 2015
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab
Barry D Hock, Lisa K Stamp, Matthew W Hayman, et al.
Tissue Antigens
|
May 14, 1999
Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56
B D Hock, D B Fearnley, A Boyce, et al.
Free Radical Biology & Medicine
|
March 8, 2020
Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin
Gregory Baxter-Parker, Hannah M Prebble, Sean Cross, et al.
Cancer Immunology, Immunotherapy : CII
|
May 24, 2025
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
Barry D Hock, Liping Goddard, Lachlan J Dobson, et al.
Clinical & Translational Immunology
|
May 8, 2026
Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide
Lachlan J Dobson, Barry D Hock, Ariana Ht Drabble, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 94) with videos related to
Sort By:
Page
of 10
The Journal of Biological Chemistry
|
January 6, 2007
JunB and JunD regulate human heme oxygenase-1 gene expression in renal epithelial cells
Thomas D Hock, Karen Liby, Marcienne M Wright, et al.
Immunology
|
October 3, 2012
Effect of activated human polymorphonuclear leucocytes on T lymphocyte proliferation and viability
Barry D Hock, Karen G Taylor, Nicholas B Cross, et al.
Leukemia & Lymphoma
|
September 17, 2004
Identification of a circulating soluble form of CD80: levels in patients with hematological malignancies
B D Hock, G C Starling, W N Patton, et al.
Internal Medicine Journal
|
November 24, 2023
Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing
Paula E Keating, Barry D Hock, Stewart M Smith, et al.
Tissue Antigens
|
February 3, 2006
Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients
B D Hock, J L O'Donnell, K Taylor, et al.
Therapeutic Drug Monitoring
|
July 30, 2015
Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab
Barry D Hock, Lisa K Stamp, Matthew W Hayman, et al.
Tissue Antigens
|
May 14, 1999
Human dendritic cells express a 95 kDa activation/differentiation antigen defined by CMRF-56
B D Hock, D B Fearnley, A Boyce, et al.
Free Radical Biology & Medicine
|
March 8, 2020
Neopterin formation through radical scavenging of superoxide by the macrophage synthesised antioxidant 7,8-dihydroneopterin
Gregory Baxter-Parker, Hannah M Prebble, Sean Cross, et al.
Cancer Immunology, Immunotherapy : CII
|
May 24, 2025
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1
Barry D Hock, Liping Goddard, Lachlan J Dobson, et al.
Clinical & Translational Immunology
|
May 8, 2026
Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide
Lachlan J Dobson, Barry D Hock, Ariana Ht Drabble, et al.
Page
of 10